Oral anticoagulants for secondary prevention of stroke

Cerebrovascular Diseases

Volumn 7, Issue , 1997, Pages 24-29

  Hart, Robert G ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; INDOBUFEN; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE;

EID: 0030728910     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108277     Document Type: Article

References (27)

1. Campbell MH: Basilar artery syndrome. Can Med Assoc J 1953;69:314-315.
2. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized clinical trials. Arch Intern Med 1994;154:1949-1957.
3. Stroke Prevention in Atrial Fibrillation Investigators: Adjustcd-dose warfarin versus low-in-tensity, fixed-dosc warfarin plus aspirin for high-risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation 111 randomized clinical trial. Lancet 1996.348:633-638.
4. European Atrial Fibrillation Trial Study Group: Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke. Lancet 1993:342: 1255-1362.
5. Olsson J, Brechter C. Bácklund H, Krook H. Muller R. Nitclius E: Antiocoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacs. Stroke 1980:11:4-9.
6. Burén A. Ygge J: Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack. Stroke 1981:12:578-580.
7. Garde A. Samuelsson K. Fahlgrcn H. Hedberg E. Hjeme L-J. Ostman J: Treatment after transient ischemic attacks: A comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke 1953:14:677-681.
8. Algra A, for the SPIRIT Investigators: Bleeding complications in patients after cerebral ischemia treated with anticoagulant drugs: Preliminary results of SPIRIT (abstract). Cerebrovasc Dis 1996;6(suppl 2):77.
9. WARSS Study Group: The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis 1997;7:100-112.
10. Levine MN. Raskob G. Hirsh J: Hemorrhagic complications of long-term anticoagulant therapy. Chest 1986:89(suppl): 16-25.
11. Hart RG. Boop BS. Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26:1471-1477.
12. Wintzen AR. De Jonge H. Loeliger EA. Botts GTAM: The risk of intracerebral hemorrhage during oral anticoagulant treatment: A population study. Ann Neurol 1984:16:533-558.
13. Hylek EM. Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994:120:897-902.
14. Eriksson SE. Link H: Evaluation of anticoagulants in patients with cerebral infarction with slight to moderate neurological deficit. Acta Neurol Scand 1983:68:96-106.
15. Link H, Lebram G. Johansson I, Ràdberg C: Prognosis in patients with infarction and TIA in carotid territory during and after anticoagulant therapy. Stroke 1979:10:529-532.
16. Whisnant JP, Cartlidge NE, Elveback LR: Carotid and vertebral-basilar transient ischemic attacks: Effect of anticoagulants, hypertension, and cardiac disorders on survival and stroke occurrence. A population study. Ann Neurol 1978:3:107-115.
17. Chimowitz MI, Kokkinos J, Strong J. Brown MB. Levine SR. Silliman S: The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995:45:1488-1493.
18. Dahl T. Abildgaard U. Sandset PM: Long-term anticoagulant therapy in cerebrovascular disease: Does bleeding outweight the benefit? J Intern Med 1995:237:323-329.
19. Hylek EM. Skates SJ. Sheehan MA. Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996:335:540-546.
20. Turpie AGG, Gent M. Laupacis A. Latour Y. Gunstensen J, Basile F: A comparison of aspirin with placebo in patients treated with warfarin and heart valve replacement. N Engl J Med 1993:329:524-529.
21. Hurlen M, Erikksen J. Smith P. Amesen H, Rollag A: Comparison of bleeding complications of warfarin and warfarin plus acctylsali-cylic acid: A study in 3.166 outpatients. J Intern Med 1994:236:299-304.
22. Morocutti C. Amabilc G. Fattaposta F. Nicolo-si A. Matteoli S. Trappolini M: Indobufen vs warfarin in the secondary prevention of major vascular events in nonrhcumatic atrial fibrillation. Stroke 1997:28:1015-1021.
23. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrhcumatic atrial fibrillation. N Engl J Med 1992:327:1406-1412.
24. Boston Area Amieoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Eng J Med 1990: 323:1505-1511.
25. European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulant therapy in patients with nonrhcumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995:333:5-10.
26. Connolly S. for the Atrial Fibrillation Investigators: Stroke Prevention in Atrial Fibrillation II Study (letter). Lancet 1994:343:1509.
27. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994:343:687-691.